The pharmacological treatment of systemic sclerosis (SSc) has been dis
couraging. In view of this, therapeutic trials with cyclosporine A (Cy
A) are outstanding particularly in patients with a rapid cutaneous inv
olvement. We report the case of a patient whose SSc cutaneous manifest
ations dramatically improved with CyA therapy. Its subsequent withdraw
al led to a quick onset of a fatal sclerodermal renal crisis. We belie
ve that in our patient there could have been a cause and effect relati
onship between the suspension of CyA and kidney sclerodermal complicat
ion.